29 DEC 2016 Alteogen patents
Date Alteogen patents (updated weekly) - BOOKMARK this page
22 DEC 2016 Alteogen clears phase 1 trial of Herceptin biosimilar in Canada
DISCLOSURE] Alteogen (196170) said on Dec. 22 that its biosimilar of Roche’s breast cancer antibody Herceptin has cleared phase 1 clinical trials in Canada.
7 Oct 2016 Alteogen receives patent in Japan
Oct 7 Alteogen Inc :
7 Mar 2016 Additional N-glycosylation in the N-terminal region of recombinant human alpha-1 antitrypsin enhances the circulatory half-life in Sprague-Dawley rats.
24 AUG 2016 Human Phase1 Clinical Data of ALT-P1 (hGH-NexP) by Healthy Korean Males
Background: ALT-P1 (CJ-40002) is a long-acting recombinant growth hormone (GH) fused with NexP, which is a long-acting carrier developed by Alteogen Inc. NexP is a protein engineered recombinant alpha